Connect with us

Cannabis News

Finally Cracking the Cannabis Consumer Code?

Published

on


cannabis consumers buy from legal sources

A recent survey conducted by Pollara Strategic Insights, a Toronto-based polling company, reveals that approximately two-thirds of Canadian consumers now exclusively purchase cannabis from legal sources. This new data, released on the fifth anniversary of the end of cannabis prohibition in Canada, suggests that the regulated cannabis industry may have a more significant share of the overall market than previously assumed. This is advantageous for compliant businesses. This finding may surprise some industry executives who have occasionally attributed their challenges and losses in the legal market to the illicit market.

 

According to the Pollara data, 65% of survey respondents reported buying only legal cannabis, a seven-point increase since November 2022. In March 2021, a Pollara survey indicated that half of consumers exclusively purchased legally sourced marijuana. Notably, the figures from Pollara surpass those from Health Canada.

 

According to Health Canada’s annual survey, approximately half of consumers consistently purchased cannabis from legal sources last year, notably lower than Pollara’s findings. This percentage marks an increase from 43% in 2021 and 37% in 2020.

 

It is essential to grasp the rough percentage of sales occurring in the legal market as it is vital for gauging the revenue available to legal businesses. The Pollara survey revealed that individuals with experience in cannabis use, both before and after legalization, are more likely to report a reduction in consumption frequency compared to the period before legalization. This suggests that legalization may have decreased cannabis consumption among these individuals.

 

The Pollara survey involved 2,006 randomly selected adults and covered various aspects of the cannabis industry. Since the survey was conducted online, a specific margin of error was not assigned. However, surveys of this scale typically carry margins of around plus or minus 2.2%. The survey brought to light some potentially concerning trends.

 

The study revealed that 27% of Canadians indicated cannabis use within the last 12 months, a substantial rise from the 11% reported in 2017. (It’s worth noting that Health Canada’s data presents a significant difference, indicating that 22% of Canadians consumed cannabis in 2017, with an increase to 27% by 2022.)

Cannabis User Purchase Patterns

Dry bud remains the most commonly used format among individuals who have used cannabis in the past 12 months, followed closely by edibles. However, considering all formats used in the past 12 months, edibles have slightly surpassed dry bud in popularity regardless of frequency.

 

Of those who have used cannabis in the past 12 months, 82% report purchasing it legally, with two-thirds (65%) stating that they exclusively acquire legal products. This reflects a notable 7-point increase in legal purchases since November 2022 and a substantial 15-point increase since March 2021.

 

A smaller proportion (13%) report obtaining cannabis through illegal means, with 4% specifying that they exclusively buy illegal products, a trend similar to our November 2022 findings. About a quarter of respondents state that they do not personally purchase cannabis; 21% mention receiving it from others or cultivating it legally (6%).

 

Individuals who have used cannabis in the past 12 months still perceive legal cannabis prices as higher (36%) or on par with illegal prices (17%). However, the perception of higher prices remains significantly lower than observed between 2019 and 2021. Currently, four in ten respondents express uncertainty about cannabis prices.

Public Approval and Perceptions

The survey also revealed that many Canadians now support cannabis legalization. Five years after cannabis was legalized on October 18, 2018, the public’s acceptance of legalization remains high at 72%. Of this, 52% express explicit approval, 20% have mixed feelings, and 23% disapprove.

 

These approval levels have remained relatively constant since 2020. Public acceptance is determined by combining approval and ambivalence. The ambivalent group effectively provides implicit approval, generally holds more positive views about cannabis and its legalization, and tends to express approval when compelled to choose.

 

Following the legalization of cannabis, the prevalence of negative public perceptions is significantly lower than the negative expectations recorded before October 2018. Presently, attitudes regarding tax revenues, the economy, and Canada’s reputation are more positive than negative. However, concerns about the health effects on youth, adults, and children, and road safety are still viewed predominantly negatively. Overall, negative perceptions are considerably lower than the public anticipated before legalization.

 

Canada primarily legalized cannabis with a focus on public health considerations. Some findings from the survey could be of potential concern for the cannabis industry, particularly those related to public health.

 

A larger proportion of Canadians (38%) believe that cannabis legalization has had a negative impact on the overall health of youth. This is in comparison to the 15% who see it as having a positive impact. Approximately one-quarter feel that there has been no impact.

Additional survey results include:

  • The benefits perceived from the legalization of cannabis, particularly in terms of economic and tax revenues, far surpass the drawbacks by a ratio of at least 2 to 1.

  • Approximately 46% of respondents express concerns that road safety has deteriorated due to cannabis legalization, while 9% believe that roads have become safer. Additionally, 27% of respondents see no substantial impact on road safety.

 

The report highlights the differences in perceived impacts of cannabis legalization between the period before 2018 and the present. Before cannabis was legalized, roughly two-thirds of Canadians thought that more young people would start using it and use it more often because of legalization. However, according to the Pollara survey, fewer than half Canadians still think this way.

Conclusion

A recent Pollara survey reveals a significant shift in Canadian cannabis consumption patterns, with 65% of respondents now exclusively buying from legal sources, indicating a stronger legal market share than previously thought. This challenges claims of industry challenges due to the illicit market.

 

However, the survey also shows increased cannabis consumption, with concerns about high prices persisting among consumers. On the positive side, public support for cannabis legalization remains high, with 72% approval. While perceptions have improved in some areas, concerns about youth impact, health, and road safety persist. The survey offers insights for industry stakeholders and policymakers.

 

LEGAL VS. ILLICIT MARKET, READ ON…

BLACK MARKET CANNABIS PRICES VS LEGAL MARKET

WHY DO PEOPLE PAY MORE FOR LEGAL WEED INSTEAD OF ILLICIT CANNABIS?



Source link

Cannabis News

Not Just Alcohol Sales Dropping, Anxiety Medication Prescriptions Plummet in States with Legal Cannabis Programs

Published

on

By


anxiety medications drop with cannabis

The legalization of marijuana has sparked a significant shift in the landscape of mental health treatment, particularly concerning anxiety disorders. Recent studies have indicated a notable decrease in prescriptions for anti-anxiety medications, especially benzodiazepines, in states where marijuana has been legalized. This phenomenon raises important questions about the implications for pharmaceutical companies that have long dominated the market for anxiety treatments. In this article, we will explore the connection between legal marijuana and the decline in anxiety medication prescriptions, delve into the broader implications for the pharmaceutical industry, and consider what this means for patients and healthcare providers.

 

Understanding Anxiety Disorders and Current Treatment Options

 

The Prevalence of Anxiety Disorders

 

Anxiety disorders are among the most common mental health issues affecting millions of individuals worldwide. According to the World Health Organization (WHO), anxiety disorders affect approximately 264 million people globally. These disorders encompass a range of conditions, including generalized anxiety disorder (GAD), social anxiety disorder, panic disorder, and specific phobias. Symptoms can vary widely but often include excessive worry, restlessness, fatigue, difficulty concentrating, and physical symptoms such as increased heart rate and sweating.

 

Traditional Treatments for Anxiety

 

Historically, treatment options for anxiety disorders have included psychotherapy and pharmacotherapy. Common pharmacological treatments include:

 

  • Benzodiazepines: Medications such as diazepam (Valium), lorazepam (Ativan), and alprazolam (Xanax) are frequently prescribed for short-term relief of acute anxiety symptoms. While effective, these medications carry risks of dependency and withdrawal symptoms.

  • Selective Serotonin Reuptake Inhibitors (SSRIs): Drugs like sertraline (Zoloft) and fluoxetine (Prozac) are often used as first-line treatments for chronic anxiety disorders. They work by increasing serotonin levels in the brain but can take several weeks to show effects.

  • Cognitive Behavioral Therapy (CBT): This form of psychotherapy is widely regarded as an effective treatment for anxiety disorders. CBT focuses on changing negative thought patterns and behaviors associated with anxiety.

 

Despite their effectiveness, many patients experience side effects from these medications or find them insufficient in managing their symptoms. As a result, there is growing interest in alternative treatments, including legal marijuana.

 

 The Rise of Legal Marijuana

In recent years, various states in the U.S. have moved toward legalizing marijuana for both medical and recreational use. As of 2023, over 30 states have legalized medical marijuana, while several others have legalized it for recreational use. This trend reflects changing public attitudes toward cannabis and increasing recognition of its potential therapeutic benefits.

 

 Medical Marijuana and Anxiety Relief

 

Cannabis contains numerous compounds known as cannabinoids, with tetrahydrocannabinol (THC) and cannabidiol (CBD) being the most studied. THC is responsible for the psychoactive effects associated with marijuana use, while CBD is non-psychoactive and has garnered attention for its potential therapeutic properties.

 

Research suggests that CBD may help alleviate anxiety symptoms without the side effects commonly associated with traditional anti-anxiety medications. A 2019 study published in The Permanente Journal found that CBD significantly reduced anxiety scores in a group of patients within a month of treatment.

 

The Connection Between Legal Marijuana and Reduced Anxiety Medication Prescriptions

 

A groundbreaking study published in JAMA Network Open examined prescription data from states that legalized marijuana. The researchers found that states with medical cannabis laws experienced a 12.4% reduction in benzodiazepine prescriptions, while those with recreational laws saw a 15.2% decrease. This data suggests that patients may be substituting cannabis for traditional anti-anxiety medications.

 

 Patient Behavior and Preferences

 

Several factors may contribute to patients’ decisions to turn to legal marijuana instead of pharmaceuticals:

 

1. Perceived Safety: Many individuals view cannabis as a safer alternative to benzodiazepines due to the latter’s association with dependency and withdrawal issues.

 

2. Efficacy: Patients often report positive experiences with cannabis in managing their anxiety symptoms, leading them to prefer it over conventional medications.

 

3. Holistic Approach: Cannabis is often perceived as part of a more holistic approach to health that includes lifestyle changes, mindfulness practices, and alternative therapies.

 

4. Accessibility: In states where cannabis is legal, obtaining it may be easier than navigating the healthcare system to secure prescriptions for traditional medications.

 

 Implications for Pharmaceutical Companies

 

The decline in benzodiazepine prescriptions linked to legal marijuana poses significant challenges for pharmaceutical companies that produce these medications. Here are some key implications:

 

Market Dynamics

 

As more patients seek cannabis as an alternative treatment for anxiety, pharmaceutical companies may face reduced demand for their products. This shift could lead to decreased revenue from anti-anxiety medications, prompting companies to reevaluate their market strategies.

 

Research and Development Focus

 

Pharmaceutical companies may need to adapt by investing in research related to cannabis-based therapies or developing new products that incorporate cannabinoids. Some companies are already exploring synthetic cannabinoids or formulations that combine traditional pharmaceuticals with cannabis extracts.

 

Regulatory Challenges

 

The evolving legal landscape surrounding cannabis presents regulatory challenges for pharmaceutical companies. As more states legalize marijuana, there may be increased scrutiny regarding its safety and efficacy compared to traditional medications.

 

Broader Implications for Mental Health Treatment

The rise of legal marijuana as a treatment option signals a potential shift in how mental health care is approached:

 

1. Integration of Cannabis into Treatment Plans: Healthcare providers may begin incorporating cannabis into treatment plans alongside traditional therapies. This integration could lead to more individualized care tailored to patients’ preferences.

 

2. Increased Focus on Patient-Centered Care:The growing acceptance of cannabis reflects a broader trend toward patient-centered care models that prioritize patient preferences and experiences in treatment decisions.

 

3. Need for Education: As patients increasingly seek information about cannabis as a treatment option, healthcare providers must be equipped with knowledge about its benefits and risks to guide informed decision-making.

 

Potential Risks and Considerations

 

While legal marijuana offers promising alternatives for managing anxiety, it is essential to consider potential risks:

 

1. Lack of Regulation:The cannabis industry is less regulated than pharmaceuticals, leading to concerns about product quality, dosing accuracy, and potential contaminants.

 

2. Individual Variability: Responses to cannabis can vary widely among individuals due to factors such as genetics, tolerance levels, and underlying health conditions.

 

3. Potential for Misuse: While many individuals use cannabis responsibly, there is potential for misuse or over-reliance on it as a coping mechanism.

 

 Conclusion

 

The link between legal marijuana and decreased prescriptions for anti-anxiety medications marks a significant development in mental health treatment paradigms. As more patients turn to cannabis as an alternative therapy, pharmaceutical companies must adapt to this changing landscape by reevaluating their strategies and investing in research related to cannabinoid-based treatments. For patients grappling with anxiety disorders, this shift could herald a new era of treatment options that prioritize safety, efficacy, and individual preferences. However, it also necessitates ongoing dialogue among healthcare providers about the best approaches to integrate cannabis into mental health care while ensuring patient safety.As we move forward into this evolving landscape of mental health treatment options, it is crucial to remain vigilant about the implications of these changes—both positive and negative—for patients seeking relief from anxiety disorders and the broader healthcare system at large.

 

 

This article provides an extensive overview of how the legalization of marijuana is linked to changes in medication prescriptions for anxiety disorders while discussing its implications on pharmaceutical companies and mental health treatment paradigms overall.

 

CANNABIS REPLACES BENZOS? READ ON…

CANNABIS FOR BENZOS

CANNABIS FOR BENZODIAZEPINES – DO THEY REPLACE THEM?



Source link

Continue Reading

Cannabis News

An Important Lesson from the 2024 Elections

Published

on

By


lesson learned in 2024 elections

Retrospect: An Important Lesson to learn from the 2024 Elections

Well folks, here we are again. Donald Trump is back in the White House, and if his previous term taught us anything, we’re strapping in for one hell of a rollercoaster ride. I can already feel my inbox filling up with requests to write about the latest Trump cannabis controversy or whatever inflammatory tweet is setting the internet ablaze.

But I’ll be honest with you – I’m going to try my damnedest to avoid turning this platform into yet another Trump commentary channel. Lord knows we’ve got enough of those already. Between the mainstream media’s obsession with every presidential syllable and the circus surrounding Elon Musk and RFK Jr.’s alliance with Trump, we’re already drowning in political theater. I mean, just look at the current media frenzy over “Did Elon Nazi Salute?” after Trump’s inauguration speech. If that’s any indication, we’re in for four years of non-stop sensationalism.

Here’s the thing though – as someone who prides himself on staying above the partisan fray (and believe me, that’s getting harder by the day), I feel obligated to share some hard-earned wisdom about navigating the cannabis landscape during these politically charged times. The last four years under Biden’s administration taught us some valuable lessons about political promises and cannabis reform, and those insights are more relevant than ever as we enter this new chapter.

So grab your favorite strain, settle into your comfy spot, and let old Reginald share some perspective on what we’ve learned and how to keep our heads straight during what’s sure to be an… interesting four years ahead.

If there’s one thing I’ve learned from years of covering cannabis politics, it’s that weed polls better than politicians – and boy, do they know it. It might sound like I’m hitting the bong too hard, but the numbers don’t lie. Election after election, cannabis legalization consistently polls higher than any candidate running for office. With pseudo-legalization spreading across the country like wildfire, there are more cannabis supporters than ever before, making us quite the tempting voting bloc.

This reality wasn’t lost on the Democrats during their four-year stint. They dangled cannabis reform like a carrot on a stick, making grand promises about prioritizing legalization. Remember Kamala Harris, suddenly becoming cannabis’s biggest cheerleader? The same Kamala who oversaw countless marijuana prosecutions as California’s Attorney General was now preaching about social justice and legalization. The irony was thicker than smoke in a hotboxed Volkswagen.

For the first few years of the Biden administration, we got nothing but lip service. Then, as election season approached – wouldn’t you know it – suddenly cannabis reform became urgent. Pot pardons! Rescheduling! It was like watching a dealer who ghosted you for months suddenly sliding into your DMs with “you up?”

And some folks ate it up. I saw countless posts from well-meaning stoners declaring their undying loyalty to Biden-Harris based solely on these eleventh-hour cannabis promises. But let’s get real – those pardons didn’t free a single soul from prison, and the rescheduling circus? Well, that’s still stuck in bureaucratic limbo, likely to face years of litigation if it ever materializes.

Here’s the kicker though – despite all this pot pandering, Trump still won. Why? Because while cannabis reform is important, Americans were more concerned about putting food on their tables, feeling safe in their communities, and managing the immigration crisis. The Democrats were so busy virtue signaling about helping marginalized communities that they forgot about the broader population’s immediate concerns. That’s like focusing on growing exotic strains while your basic crops are dying – it might sound cool, but it won’t feed the masses.

The result? Not only did they lose the election, but they strung along millions of cannabis supporters for absolutely nothing. No legalization, no meaningful reform, just empty promises and disappointed voters. And therein lies our lesson, my friends. Politicians will always love pot pandering because they know we’re passionate about legalization. But when their promises go up in smoke, we’re the ones left holding an empty bag.

Here’s a draft in Reginald Reefer’s voice:

Let me tell you why I stay away from political parties like they’re contaminated bathwater. It’s not because I don’t care about society or our collective rights – quite the opposite. It’s because these parties are like ill-fitting suits; they might look good on the rack, but once you try them on, nothing quite sits right.

Take me, for example. On some issues, I’m as “Republican” as they come. I believe in keeping government small (because let’s face it, they tend to mess up everything they touch), rewarding merit over handouts, cutting through red tape, and protecting individual liberties. You know, the whole “leave me alone to grow my plants in peace” mentality.

But flip the coin, and suddenly I’m singing from the Democratic hymnal. I believe in drug reform (obviously), holding big corporations accountable for their shenanigans, protecting Mother Earth, and letting people love whoever they damn well please. Some might say this makes me a libertarian, but I prefer to think of myself as an anarchist – not in the “chaos in the streets” sense, but in the “I don’t need a master telling me what to do” sense.

Now, if I were to play the political game (which I’m not, but let’s pretend), here’s how I’d approach it. During campaign season? Sure, I’d fight like hell to get my candidate in office. Wave the signs, spread the word, do the whole song and dance. But the moment they win? That’s when the real work begins.

See, this is where most people get it wrong. They treat their political party like a sports team, blindly cheering even when their players are dropping the ball. But that’s not how democracy should work. The minute your candidate takes office, you need to transform from their biggest cheerleader into their harshest critic.

Stop swooning over their tweets and start scrutinizing their actions. Forget what they promised on the campaign trail – what are they actually doing now? Are they following through, or are they just blowing smoke? If they’re not living up to their word, it’s time to make some noise. Call your representatives, flood their offices with emails, make your voice heard.

That’s the thing about political promises – they’re like rolling papers in the wind unless someone holds these politicians accountable. And who better to do that than the people who put them in office? Don’t let them get comfortable. Don’t let them forget who they work for.

So over these next four years, whether you’re a Trump supporter or just someone trying to navigate this political circus, remember: Your job isn’t to defend your candidate’s every move. Your job is to keep them honest, keep them working, and keep them afraid of disappointing their constituents. Because at the end of the day, politicians are like cannabis plants – they need constant attention and occasional pruning to produce anything worthwhile.

Let’s talk about the orange elephant in the room. Love him or hate him, Trump isn’t your typical politician – mainly because he isn’t one. He’s more like a chaos wizard who somehow got hold of the nuclear codes. But here’s the thing that makes covering Trump so interesting: unlike most politicians who make promises they never intend to keep, this guy actually follows through on some wild stuff.

Take his first few weeks back in office. While the media was having a meltdown about his latest tweet, Trump was busy declassifying JFK and MLK documents that have been gathering dust for decades. But the real head-turner? Pardoning Ross Ulbricht, aka the Dread Pirate Roberts. Here’s a guy who got two life sentences without parole for… what exactly? Creating a website? Sure, people sold drugs on the Silk Road, but by that logic, we should throw Mark Zuckerberg in prison every time someone sells weed through Facebook Messenger.

And he’s not done. RFK Jr. – the black sheep of the Kennedy family who’s been raising hell about pharmaceutical companies – is set to head Health and Human Services. Meanwhile, Trump’s already making good on his immigration promises faster than you can say “build the wall.” It’s clear this isn’t the same Trump from 2016. He’s got new allies, new strategies, and seemingly fewer fucks to give than ever before.

But here’s where things get murky, folks. While Trump’s making moves that have libertarians and anti-establishment types cheering, he’s also cozying up to some seriously sketchy characters. Take Larry Ellison, the Oracle overlord who’s got deeper CIA connections than my grow room has spider mites. For those who don’t know, Oracle started as a CIA project in 1977 with Ellison at the helm, though they’ll swear up and down it’s all ancient history. Yeah, and I’m just growing tomatoes in my basement.

What’s particularly concerning is all this talk about using AI to develop mRNA vaccines. I don’t know about you, but combining artificial intelligence, experimental vaccines, and a company with intelligence agency roots sounds like the plot of a dystopian novel I don’t want to live through.

So here we are, watching Trump do some genuinely positive things while simultaneously setting up what could be the infrastructure for a technocratic surveillance state. It’s like finding out your dealer is giving you great prices but also installing cameras in your house. Sure, the weed’s good, but at what cost?

This is why, my friends, we need to stay vigilant. Celebrate the wins when they come, but keep your eyes wide open and your bullshit detectors finely tuned. Because in Trump’s America 2.0, the only thing we can be certain of is uncertainty itself.

 

TRUMP ON MARIJUANA LEGALIZATION, READ ON…

TRUMP MARIJUANA LEGALIZATION

WHAT WILL TRUMP 2.0 DO ABOUT LEGALIZING WEED? WE ASKED!



Source link

Continue Reading

Cannabis News

Oregon Cannabis 2025: Legislative Forecast and Report

Published

on

By


The Oregon legislative session formally kicked off this week, on Tuesday, January 21st. It’s a regular session in 2025, meaning we’re in for a longer stretch — a 160-day calendar, versus the 35-day affair we see in even-numbered years.

If you read any of the news articles previewing the 2025 session, you won’t see cannabis as a legislative priority. Most likely, you won’t see it mentioned at all. Legislators seem both wary and weary of cannabis: the 2023 industry scandals implicating public officials are still fairly recent; and, after ten dynamic years and hundreds of adult use cannabis proposals, bills and laws, the program needs to breathe.

All of that said, the Cannabis Industry Association of Oregon (CIAO) and others have been working on their wish lists, and I do expect to see a few new cannabis laws in 2025. Most of it will be scaffolding and maintenance.

Below, I summarize the draft bills currently teed up in the 2025 session (with links), and give some cursory comments. But first I’ll add my usual caveat: a large majority of these introduced bills will not pass. Some contain overlapping concepts and will never go to committee, while others will fail after a hearing or two, or be consolidated into omnibus or placeholder bills.

This is one of the omnibus bills, and one to watch. Its drafter described it to me yesterday as “omnibus but not complete,” in fact. Here’s what’s in there as of today:

  • Authorizes the destruction of hoop houses when executing a search warrant to investigate the unlawful production of marijuana.
    • This strikes me as potentially problematic, as a due process issue.
  • Requires the OLCC to make maps of licensed industrial hemp operations and marijuana production premises available to the Water Resources Department and the Department of Environmental Quality.
    • An inter-agency communication issue. Been on the list for a while.
  • Repeals the prohibition on a marijuana retailer locating within 1,000 feet of a building where a public prekindergarten or kindergarten program is provided.
    • Something we’ve dealt with more than once, including with the Department of Justice way back when. Just a clarification needed.
  • Allows the State Department of Agriculture to inspect biomass and processed industrial hemp stored at the location of a licensed industrial hemp operation.

Here are a few concepts that may be added:

  • Grant OLCC authority to move from a one-year licensing cycle to a two-year cycle, as with alcohol.
    • This could cut a lot of red tape for both OLCC and industry. The devil would be in the details as to marijuana retailer tax issues, but as a concept I really like it.
  • Re-up the grant program targeting illegal grows in southwest Oregon, at current service levels.
    • This grant has been around since 2018: the sheriffs and victim’s rights folks are the main proponents. If you’d like to see data, the Oregon Criminal Justice Commission program published a recent report here.
  • Requires OHA to study the medical use of marijuana.
    • This is a funny little bill and probably just a placeholder. We’ve only had a medical marijuana statute in Oregon for 27 years!
  • Removes requirements that a registry identification cardholder who produces marijuana for personal medical use register with OHA.
  • Requires a person responsible for a marijuana grow site that produces marijuana for medical use for three or more registry identification cardholders to apply for a designation from the OLCC.
  • Directs OHA to issue electronic registration cards.
  • Requires marijuana retailers to offer for sale medical grade cannabinoid items that contain not more than 20 percent total THC.
  • Creates health care and employment protections for a person who is a registry identification cardholder.

This is an Oregon Cannabis Commission bill with some strong concepts, but it will need a lot of amending. OLCC has been slowly absorbing OHA’s medical marijuana program for years. At first that upset people, but a full windup is a fait accompli. SB 162 has a good chance to pass in some form.

  • Requires OLCC to study cannabis.
  • Directs OLCC to submit findings to the interim committees of the Legislative Assembly related to the judiciary not later than September 15, 2026.

Placeholder.

Same as SB 188. Placeholder.

  • Ends special tax assessment for land, if the owner or the person in control of the land gets a civil penalty for growing marijuana on the land or is found guilty of growing it there.
  • Makes an exception if the owner reasonably didn’t know about the pot or called the police as soon as they did know.
  • Disqualifies land from farm use special assessments upon a final civil penalty or judgment of conviction for the illegal growing of marijuana against the landowner or person in possession and control of the land.
  • Provides an exception for a landowner or other obligated taxpayer who reasonably lacked knowledge of the illegal growing of marijuana or promptly notified a law enforcement agency of the illegal growing of marijuana.

This bill appears to be poorly conceived and poorly structured at present. I’m guessing it doesn’t go anywhere for several reasons, not least of which will be the fiscal impact consideration.

  • One-liner: establishes a division in the Department of State Police to enforce laws related to illegal marijuana cultivation.

I doubt it goes anywhere.

This one, along with SB 557 and 558 just below, are the CIAO bills. (You can view CIAO’s legislative priorities here.) Each of these bills are sponsored by Senator Floyd Prozanski, longtime industry supporter.

  • Allows a marijuana producer, marijuana wholesaler, marijuana processor or marijuana retailer to use a motion detection camera system at a licensed premises.
    • I was surprised this would be disallowed by OLCC.
  • Directs OLCC to establish by rule an industrial hemp endorsement for marijuana producers.
  • Prohibits OLCC from requiring physical tags or other identifiers on certain marijuana plants.
    • This would be very useful and cut down on lots of pointless “compliance” and labor and waste.
  • Allows a marijuana item transport vehicle to use a digital manifest and edit the manifest during transport.
    • Let’s get with the times.
  • Allows the State Department of Agriculture (ODA) to define “industrial hemp” by rule.
  • Allows a marijuana licensee to engage in the interstate commerce of industrial hemp and marijuana. Becomes operative if federal law or the United States Department of Justice allow or tolerate the interstate commerce of industrial hemp or marijuana.
    • I need to ask about this too. In 2019, we passed SB 582 which already allows export of marijuana when the federal environment changes. This proposal seems very similar.
  • Requires at least one OLCC commissioner to hold a marijuana processor, marijuana producer, marijuana retailer or marijuana wholesaler license.

Creative, and probably going nowhere.

  • Allows a marijuana licensee to provide samples of marijuana items to other marijuana licensees at temporary events registered with OLCC.
  • Allows the commission to establish by rule a temporary events registration system. Allows a marijuana wholesaler to sell marijuana items to a marijuana retailer at a temporary event.
  • Allows a marijuana producer to provide samples of seeds and immature marijuana plants to permitted workers.
  • Allows a marijuana producer, marijuana processor and marijuana wholesaler to provide samples of marijuana items in specified amounts to permitted workers.

A bunch of rulemaking coming up for OLCC if this passes. But it all makes sense.

  • Increases the maximum percentage of tax that the governing body of a city or county may impose on the sale of marijuana items. 20% of the proceeds go to the city or county at issue.
  • Requires a percentage of a newly enacted or increased amount to be transferred to the county in which the collecting retail establishment is located, provided the county is eligible for Oregon Marijuana Account distributions.

This will get the cannabis industry’s hackles up, severely. Similar bills have been beaten back in prior years and I expect the same result here.

  • Establishes a state public bank task force.

The Governor vetoed this bill last time around, citing “logistical challenges.” I haven’t had a chance to talk with the sponsors of SB 583, so I’m not sure what the plan is on reintroduction. As a guy from North Dakota — the only state in the union with a state-chartered bank; and as an equitable banking access proponent — I hope this one succeeds.

  • Exempts from public records disclosure the residential address or personal phone number of an individual who holds a permit issued under ORS 475C.273.

The reference there is to marijuana worker permits. Good idea. The proposed law should probably sweep in ORS 475C.269 as well.

  • States that the person must tell the OHA or the OLCC where the person plans to grow, process or produce the marijuana or psilocybin and who owns the site that the person plans to use. Specifies some cases when the OHA or the OLCC cannot give permission to the person.
  • Requires an applicant for a license to manufacture psilocybin to submit to OHA information regarding the ownership and location of the premises to be licensed, and prohibits the authority from issuing a license in specified circumstances.
  • Requires an applicant for a license to produce or process marijuana to submit to the OLCC information regarding the ownership and location of the premises to be licensed. Prohibits the commission from issuing a license in specified circumstances.
  • Requires an applicant for a medical marijuana grow site or medical marijuana processing site registration to submit to the authority information regarding the ownership and location of the premises to be registered. Prohibits OHA from issuing a registration in specified circumstances.

This is a big and rangy bill with concepts overlapping some of the others. Expect it to be absorbed somewhere, in some form.

  • Provides items that have cannabis in them must have a label that says a person has to be at least 21 years old to consume or use the item.
  • Requires labels on marijuana items and inhalant delivery systems that contain industrial hemp-derived vapor items to include that the minimum age for consumption or use is 21 years of age.

Everyone would have to re-do their labels.

  • Requires that marijuana items and stores warn people that the use of marijuana by a person who is pregnant might cause danger.
  • Requires a marijuana retailer and a medical marijuana dispensary to post warning signs regarding the consumption or use of marijuana during pregnancy.
  • Requires marijuana items and inhalant delivery systems that contain an industrial-hemp derived vapor item to include in labeling that consumption or use of marijuana during pregnancy may be dangerous.

Some speech and label issues here.

  • Requires OLCC to study itself. Directs OLCC to submit findings to the interim committees of the Legislative Assembly related to economic development not later than September 15, 2026.

Placeholder. Same as 2276.

Similar to the two above.

  • Directs OLCC to look at cannabis and report to the judiciary committees. Directs the commission to submit findings to the interim committees of the Legislative Assembly related to the judiciary not later than September 15, 2026.

I believe this one also comes via the Oregon Cannabis Commission, like SB 176. And like SB 176, it likely has legs but will also see some amendments along the way.

  • Provides that organizations that provide hospice, palliative care or home health care services, as well as certain residential facilities, must write policies and teach their staff about the medical use of marijuana.
  • Same requirement of any such organization or residential facility that is designated as an additional caregiver for a medical marijuana cardholder.
  • Protects an organization or residential facility and its employees and contractors from certain criminal liability related to the medical use of marijuana.
  • Prohibits the Oregon State Board of Nursing from taking disciplinary action against a nurse for discussing the medical use of marijuana with a patient. (Note: nurses are already allowed by statute to discuss medical marijuana use with patients, consistent with First Amendment protections)
  • Expands the definition of “debilitating medical condition” for the medical use of marijuana. The specific add-on I’m seeing is “the need for hospice, palliative care, comfort care or other symptom management, including comprehensive pain management.”

______

That’s all she wrote for now. I’ll check in again at the end of the session, or before that with any significant developments.

 



Source link

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media